Apimeds Pharmaceuticals US Files Initial Beneficial Ownership Statement for Co-CEO Vin Menon

• Apimeds Pharmaceuticals US Co-CEO Vin Menon disclosed Series A Convertible Preferred Stock underlying 484,775 common shares in an initial ownership filing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apimeds Pharmaceuticals US Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0002099463-26-000001), on November 02, 2026, and is solely responsible for the information contained therein.